Free Republic

Quote from the video; "The Red Cross says anyone who has received their vaccine cannot donate convalescent plasma to help other Covid-19 patients in hospitals. That plasma is made up of antibodies from people who have recovered from the virus, but the vaccine wipes out those antibodies, making the convalescent plasma ineffective in treating other Covid-19 patients." The Red Cross doesn't want Blood from the Vaccinated (bitchute.com)

President Donald Trump announced on Aug. 23 the emergency authorization of convalescent plasma to treat the CCP virus. “I’m pleased to make a truly historic announcement … that will save thousands of lives,” Trump said, describing it as a “breakthrough in a fight” against the CCP (Chinese Communist Party) virus. Trump announced that the Food and Drug Administration (FDA) made an emergency-use authorization of convalescent plasma for the virus, saying it is “safe and very effective.” He said the treatment will reduce mortality from the virus by about 35 percent. Convalescent plasma treatments use blood from COVID-19 patients who have...

WASHINGTON (AP) — After expressing frustration at the slow pace of approval for coronavirus treatments, President Donald Trump was set to announce on Sunday the emergency authorization of convalescent plasma for COVID-19 patients. The announcement will come after days of White House officials suggesting there were politically motivated delays by the Food and Drug Administration in approving a vaccine and therapeutics for the disease that has upended Trump’s reelection chances. On the eve of the Republican National Convention, Trump was set to issue the emergency order — which would make it easier for some patients to obtain the treatment —...

A new study shows that an experimental procedure that uses convalescent plasma—essentially blood from recovered patients—to treat COVID-19 is safe.Researchers from Mayo Clinic, Michigan State University, and Johns Hopkins University, tracked 5,000 patients who received convalescent plasma transfusions and found few side effects and low mortality in those receiving the experimental treatment.The study, a pre-print version not yet peer-reviewed, was posted Thursday on a health sciences server called Medrxiv (pdf). Pre-print studies report new medical developments that are not yet approved to be used to guide medical practice. The researchers measured the impact of convalescent plasma transfusions on hospitalized...